Completed Cancer Infection & Immunity

Exploring innate-like and adaptive gamma delta T cell paradigms in health and disease

In plain English

AI plain-English summary

A type of immune cell called a γδ T-cell has been preserved in vertebrates for roughly 500 million years, yet scientists still do not fully understand how it recognises threats or what role it plays in the body. This matters because γδ T-cells are increasingly seen as promising targets for new therapies, but the lack of basic knowledge about their biology has held back progress. The research addresses several unresolved questions: how these cells behave in different tissues, how they coordinate with other immune responses, and how they change during inflammation and cancer. The team will identify the molecular targets that γδ T-cells recognise, focusing on a family of molecules called Butyrophilins that have emerged as critical ligands. They will also use cytomegalovirus infection as a model to find new ligands for adaptive-like γδ T-cell subsets, and develop imaging techniques to visualise these cells in solid tissues. This is fundamental science. If successful, it will provide the foundational understanding needed to design therapies that harness γδ T-cells against infection and cancer. Similar fundamental work on other immune cells has already led to breakthroughs like checkpoint inhibitor drugs and CAR-T cell therapy.

View original technical description
γδ T-cells have been retained in vertebrates for ~500million years, and are of increasing therapeutic interest, but their mode of ligand recognition and immunological niche has remained largely mysterious. Here we build on the emergence of parallel innate-like and adaptive human γδ T-cell paradigms to address unresolved ‘keystone’ questions in γδ T-cell biology. Firstly, we will exploit multidisciplinary approaches to explore the diversity of innate-like and adaptive γδ biology in different tissues, their coordination with other immune responses, and how these change in disease states such as inflammation and cancer. Secondly, we will identify molecular targets of γδ-TCRs from innate-like subsets and structurally characterise their TCR/ligand interactions and cellular/molecular recognition mechanisms, focussing significantly on the strong emergence of Butyrophilin family molecules as critical TCR-ligands for such populations. Thirdly we will exploit cytomegalovirus infection as a unique human model to identify novel ligands for antigen-experienced adaptive-like γδ T-cell subsets. Finally, we will develop and apply new methodology to image and phenotype distinct human γδ T-cell subsets in solid tissues, using multispectral immunofluorescence and digital spatial profiling. This programme should help revolutionise our understanding of γδ T-cells, and provide a solid foundation for ongoing efforts to therapeutically harness the γδ T-cell compartment.

View the original record at the funder ↗

Researchers

Benjamin Willcox (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

Unconventional dynamics: turnover, structure and maintenance of the γδ T cell population in humans
Understanding thymic acquisition of gamma/delta T cell effector function
The molecular basis of gamma delta T cell recognition in health and disease.
Control of mucosal immunity and intestinal integrity by human gamma/delta T cells
Human gamma delta T cells: from fundamental biology to cancer immunotherapy

Original classification

Investigator Award in Science

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.